Clinical trials: Behavioral Activation Treatment
Major Depressive Disorder
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to explore patterns of Brain Network Activation (BNA) changes from baseline to endpoint on 1) efficacy of core symptoms of Major Depressive Disorder (MDD) and 2) improvement of cognitive dysfunction…
- Trial name
- NCT02749721
- Testing
- vortioxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rush University Medical Center
Multiple Sclerosis, Fatigue
Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
This prospective case series will use mixed methods to examine the feasibility, acceptability, and initial effects of three telehealth cognitive behavioral therapy components (relaxation training, behavioral activation, cognitive…
- Trial name
- NCT05848323
- Testing
- 4-week Relaxation Training, 4-week Behavioral Activation, 4-week Cognitive Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Autism Spectrum Disorder
FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
This is an 8 week research study of aripiprazole (abilify) which is used to reduce irritable behaviors in autism spectrum disorders. All participants will receive active study medication.
- Trial name
- AripfMRI (NCT01028820)
- Testing
- Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes Mellitus With Hypoglycemia, Aging
Prepare for Your Diabetes Care
As adults with type 2 diabetes age, they are increasingly vulnerable to treatment-related hypoglycemia and its related complications (including hospitalization and death).
- Conditions
- Type 2 Diabetes Mellitus With Hypoglycemia, Aging, Patient Activation
- Trial name
- NCT05263310
- Testing
- Prepare for Your Diabetes Care, Usual Care
- Where
- United States
- Volunteers
- 672 people
- Sponsor
- Kaiser Permanente
Chronic Pain
Patient Activation to Address Chronic Pain and Opioid Management in Primary Care
Will a primary care-based behavioral intervention for patient activation and engagement and self-management, for patients with chronic pain who are taking opioid pain medication, result in better patient outcomes than Usual Care?
- Trial name
- NCT02290223
- Testing
- Behavioral Based Treatment Model
- Where
- 2 sites in United States
- Volunteers
- 376 people
- Sponsor
- Kaiser Permanente
Mental Disorders
Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation
The purpose of this study is to learn more about how patients and healthcare providers interact in order to improve shared decision making.
- Trial name
- PCORI (NCT01947283)
- Testing
- DECIDE-PA, DECIDE-PC
- Where
- 8 sites in United States
- Volunteers
- 481 people
- Sponsor
- Massachusetts General Hospital
Kidney Diseases, Cardiometabolic Risk Factors
Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi)
The purpose is to explore the feasibility and acceptability of participation in a decision-support training program led by lay navigators.
- Trial name
- ImPart-Multi (NCT06067009)
- Testing
- ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Alabama at Birmingham
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Posttraumatic Stress Disorder, Depression
Behavioral Activation for PTSD/Depression Treatment in OIF/OEF Veterans
The present study is a randomized, controlled trial that compares Behavioral Activation (BA) to Treatment As Usual (TAU) in PTSD Specialty clinics, as early psychotherapeutic interventions for OIF/OEF veterans with posttraumatic…
- Trial name
- NCT00805532
- Testing
- Behavioral Activation treatment, Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- VA Office of Research and Development
Thyroid Cancer
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
This study plans to learn more about a drug called bexarotene for the treatment of advanced thyroid cancer. Subjects are asked to be in this study because they have thyroid cancer that will not respond to radioactive iodine…
- Trial name
- NCT00718770
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company